New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday announced that clinical trials of Covid-19 vaccine Covovax have started in India and that the company plans to launch it by September this year.
In August 2020, American vaccine company Novavax Inc, had announced a license agreement with Serum Institute of India for the development and commercialisation of NVX-CoV2373, in low and middle-income countries and India.
“Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #Covid19 and has an overall efficacy of 89%. Hope to launch by September 2021!,” Poonawalla announced in a tweet.
